Drug General Information
Drug ID
D07MVK
Former ID
DAP000953
Drug Name
Halofantrine
Synonyms
Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
Drug Type
Small molecular drug
Indication Malaria [ICD10:B54] Approved [538542]
Therapeutic Class
Antimalarials
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL

Formula
C26H30Cl2F3NO
Canonical SMILES
CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F<br />)(F)F)O
InChI
1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
InChIKey
FOHHNHSLJDZUGQ-UHFFFAOYSA-N
CAS Number
CAS 69756-53-2
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
P01BX01
SuperDrug CAS ID
cas=069756532
Target and Pathway
Target(s) Calmodulin Target Info Modulator [556264]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Phosphatidylinositol signaling system
Oocyte meiosis
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Circadian entrainment
Long-term potentiation
Neurotrophin signaling pathway
Dopaminergic synapse
Olfactory transduction
Phototransduction
Inflammatory mediator regulation of TRP channels
Insulin signaling pathway
GnRH signaling pathway
Estrogen signaling pathway
Melanogenesis
Oxytocin signaling pathway
Glucagon signaling pathway
Salivary secretion
Gastric acid secretion
Alzheimer's disease
Amphetamine addiction
Alcoholism
Pertussis
Tuberculosis
Glioma
NetPath Pathway RANKL Signaling Pathway
TSH Signaling Pathway
PANTHER Pathway CCKR signaling map ST
Pathway Interaction Database BCR signaling pathway
p38 MAPK signaling pathway
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Role of Calcineurin-dependent NFAT signaling in lymphocytes
IL2 signaling events mediated by PI3K
IFN-gamma pathway
Lissencephaly gene (LIS1) in neuronal migration and development
ErbB1 downstream signaling
VEGFR1 specific signals
Regulation of cytoplasmic and nuclear SMAD2/3 signaling
Calcium signaling in the CD4+ TCR pathway
Signaling events mediated by VEGFR1 and VEGFR2
Insulin-mediated glucose transport
N-cadherin signaling events
Cellular roles of Anthrax toxin
Regulation of Ras family activation
Downstream signaling in na&#xef
PathWhiz Pathway Muscle/Heart Contraction
Reactome Calmodulin induced events
Platelet degranulation
Translocation of GLUT4 to the plasma membrane
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
DARPP-32 events
eNOS activation
Inactivation, recovery and regulation of the phototransduction cascade
FCERI mediated Ca+2 mobilization
Ca2+ pathway
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
Smooth Muscle Contraction
VEGFR2 mediated vascular permeability
VEGFR2 mediated cell proliferation
RHO GTPases activate IQGAPs
RAF/MAP kinase cascade
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Translocation of GLUT4 to the Plasma Membrane
Visual phototransduction
Fc epsilon receptor (FCERI) signaling
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Signaling by the B Cell Receptor (BCR)
Inositol phosphate metabolism
DAG and IP3 signaling
Opioid Signalling
Muscle contraction
Metabolism of nitric oxide
Metabolism of carbohydrates
References
Ref 538542FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.